Logo

uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

Share this
uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

Shots:

  • The DSMB recommended continued the dosing in the P- I/II clinical trial assessing AMT-130 in patients with a second higher-dose cohort- after review safety data from the first cohort of ten patients
  • The first cohort of P- I/II trial for AMT-130 in 10 patients out of which six patients received treatment with AMT-130 and four patients received imitation surgery for early manifest HD. UniQure will now begin to enroll patients in the higher-dose cohort of the trial
  • The company initiates clinical development of the therapy in Europe in H2’21 and share initial imaging and biomarker data from the US clinical trial in 2021

  Ref: Globe Newswire | Image: STAT News

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions